Cargando…

Was EU’s COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations

AIM: The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts in 2020 before the approval of the first COVID-19 vaccine. This study aimed to retrospectively analyze the EU’s COVID-19 vaccine procurement strategy. To this end, the study...

Descripción completa

Detalles Bibliográficos
Autor principal:	Gandjour, Afschin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694594/ https://www.ncbi.nlm.nih.gov/pubmed/36434631 http://dx.doi.org/10.1186/s12913-022-08726-4

Ejemplares similares

Value-based pricing of a COVID-19 vaccine
por: Gandjour, Afschin
Publicado: (2022)

Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective
por: Gandjour, Afschin
Publicado: (2022)

How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
por: Gandjour, Afschin
Publicado: (2021)

Long COVID: Costs for the German economy and health care and pension system
por: Gandjour, Afschin
Publicado: (2023)

A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
por: Gandjour, Afschin
Publicado: (2023)

A parsimonious model to validate cost-effectiveness analyses on preventive health care
por: Gandjour, Afschin
Publicado: (2021)

COVID-19 and the forgone health benefits of elective operations
por: Gandjour, Afschin
Publicado: (2022)

Financial Incentives in the Path to Recovery from the COVID-19 Pandemic
por: Gandjour, Afschin
Publicado: (2021)

Optimal allocation of scarce PCR tests during the COVID-19 pandemic
por: Gandjour, Afschin
Publicado: (2023)

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
por: Gandjour, Afschin
Publicado: (2020)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy
por: Shaikh, Mujaheed, et al.
Publicado: (2018)

The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany
por: Gandjour, Afschin
Publicado: (2022)

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG
por: Gandjour, Afschin
Publicado: (2020)

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency
por: Gandjour, Afschin
Publicado: (2020)

Deterministic Sensitivity Analysis Under Ignorance
por: Gandjour, Afschin
Publicado: (2021)

The price of curing cancer
por: Gandjour, Afschin
Publicado: (2021)

Demonstrating the value of cancer biomarkers at the population level
por: Gandjour, Afschin
Publicado: (2022)

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023)

EU’s Ordering of COVID-19 Vaccine Doses: Political Decision-Making under Uncertainty
por: Gleißner, Werner, et al.
Publicado: (2021)

Direct evidence for significant spin-polarization of EuS in Co/EuS multilayers at room temperature
por: Pappas, S. D., et al.
Publicado: (2013)

Costs of patients with chronic kidney disease in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

The EU’s Pandemic Response: Tackling COVID-19, Building the Future
por: Gentiloni, Paolo
Publicado: (2020)

Identity Narratives in China and the EU’s Economic Diplomacy: Comparing the BRI and the EU Connectivity Strategy for Asia
por: Holzer, Constantin
Publicado: (2020)

Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model
por: Adarkwah, Charles Christian, et al.
Publicado: (2011)

Rational and irrational vaccine hesitancy
por: Green, Manfred S.
Publicado: (2023)

Stress Perception and Coping Strategies of Students on Both Sides of the EU’s Eastern Border during the COVID-19 Pandemic
por: Shpakou, Andrei, et al.
Publicado: (2022)

Irrationality /
por: Bortolotti, Lisa
Publicado: (2015)

Planning for future COVID-19 vaccine procurement
por: Teerawattananon, Yot, et al.
Publicado: (2022)

Monitoring What Governments “Give for” and “Spend on” Vaccine Procurement: Vaccine Procurement Assistance and Vaccine Procurement Baseline
por: Nelson, E. A. S., et al.
Publicado: (2014)

Irrational Consumption during the COVID-19 Period
por: Yu, Wenhuan, et al.
Publicado: (2022)

Crisis and Intergovernmental Retrenchment in the European Union? Framing the EU’s Answer to the COVID-19 Pandemic
por: Salvati, Eugenio
Publicado: (2020)

Will COVID-19 lead to a major change of the EU Public Health mandate? A renewed approach to EU’s role is needed
por: Clemens, Timo, et al.
Publicado: (2020)

Irrational numbers /
por: Niven, Ivan, 1915-1999
Publicado: (1956)

Irrational numbers
por: Niven, Ivan
Publicado: (1956)

The greeks and the irrational
por: Dodds, E. R. 1893-1979 (Eric Robertson)

Irrational Beliefs
por: Žeželj, Iris, et al.
Publicado: (2019)

Irrational restrictions
por: Andrews, June
Publicado: (2020)

Evaluating the effectiveness of the EU’s approach to the sustainable use of pesticides
por: Helepciuc, Florența-Elena, et al.
Publicado: (2021)

Analysing the EU’s collective securitisation moves towards China
por: Chen, Xuechen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_97qvk2ddsfj03h6daftl22amj5